Detail akcie Personalis Rg online

Business Summary: Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Personalis Inc revenues decreased 23% to $52.3M. Net loss decreased 11% to $57.5M. Revenues reflect United States segment decrease of 31% to $47.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.14 to -$0.65.